menu
menu
February 01, 2020
Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. (See DX Deals on page 1 for the details.) Here are the 10-highest value M&A diagnostics deals that did come off in 2019.
Top 10 Lab M&A Deals of 2019
|
Rank |
Buyer |
Target |
Reported Price |
|
1 |
Danaher |
GE Biopharma |
$21.4 billion |
|
2 |
Exact Sciences |
Genomic Health |
$2.8 billion (cash + stock) |
|
3 |
Thermo Fisher Scientific |
Brammer Bio |
$1.7 billion |
|
4 |
Agilent Technologies |
BioTek Instruments |
$1.17 billion |
|
5 |
PHC Holdings (formerly known as Panasonic Healthcare Holdings) |
Thermo Fisher Scientific |
$1.14 billion |
|
6 |
Sartorius |
Danaher |
$750 million* |
|
7 |
Covance Drug Development (part of LabCorp) |
Envigo |
$485 million |
|
8 |
Beckman Coulter Life Sciences |
Labcyte |
$308 million |
|
9 |
PerkinElmer |
Cisbio Bioassays |
$219.8 million |
|
10 |
Clayton, Dubilier & Rice investment funds |
Cynosure (owned by Hologic) |
$205 million |
* Announced in 2019 with closing scheduled for 2020
**************
This article originally appeared in G2 Intelligence, Laboratory Industry Report, January 2020
ADVERTISEMENT